(Q34340186)

1 August 2017

title

Malaria vaccine R&D in the Decade of Vaccines: breakthroughs, challenges and opportunities (English)

1 reference

1 August 2017

0 references

1 reference

1 reference

Vasee S Moorthy

2

0 references

Chetan Eknath Chitnis

object named as

Chetan E Chitnis

4

0 references

author name string

Ashley J Birkett

1

1 reference

1 August 2017

Christian Loucq

3

1 reference

1 August 2017

David C Kaslow

5

1 reference

1 August 2017

language of work or name

English

0 references

publication date

1 April 2013

1 reference

1 August 2017

1 reference

1 August 2017

volume

31 Suppl 2

1 reference

1 August 2017

page(s)

B233-43

1 reference

Malaria. Did they really say ... eradication?

1 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.02.040

A Research Agenda to Underpin Malaria Eradication

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.02.040

A research agenda for malaria eradication: vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.02.040

Aligning new interventions with developing country health systems: target product profiles, presentation, and clinical trial design

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.02.040

A review of malaria vaccine clinical projects based on the WHO rainbow table

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.02.040

The malaria vaccine candidate RTS,S/AS is in phase III clinical trials

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.02.040

Design of a phase III multicenter trial to evaluate the efficacy of the RTS,S/AS01 malaria vaccine in children across diverse transmission settings in Africa

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.02.040

Development of the RTS,S/AS malaria candidate vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.02.040

Measurement of malaria vaccine efficacy in phase III trials: report of a WHO consultation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.02.040

MALVAC 2008: Measures of efficacy of malaria vaccines in phase 2b and phase 3 trials--scientific, regulatory and public health perspectives

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.02.040

Statistical methodology for the evaluation of vaccine efficacy in a phase III multi-centre trial of the RTS, S/AS01 malaria vaccine in African children

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.02.040

First results of phase 3 trial of RTS,S/AS01 malaria vaccine in African children

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.02.040

Safety and efficacy of the RTS, S/AS01 E candidate malaria vaccine given with expanded-programme-on-immunisation vaccines: 19 month follow-up of a randomised, open-label, phase 2 trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.02.040

Evaluation of the safety and immunogenicity of the RTS,S/AS01 E malaria candidate vaccine when integrated in the expanded program of immunization

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.02.040

GlaxoSmithKline Adjuvant Systems in vaccines: concepts, achievements and perspectives

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.02.040

Protection against a malaria challenge by sporozoite inoculation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.02.040

Randomized, double-blind, phase 2a trial of falciparum malaria vaccines RTS,S/AS01B and RTS,S/AS02A in malaria-naive adults: safety, efficacy, and immunologic associates of protection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.02.040

Safety and clinical outcome of experimental challenge of human volunteers with Plasmodium falciparum-infected mosquitoes: an update

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.02.040

Experimental human challenge infections can accelerate clinical malaria vaccine development

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.02.040

Protection of humans against malaria by immunization with radiation-attenuated Plasmodium falciparum sporozoites

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.02.040

Live attenuated malaria vaccine designed to protect through hepatic CD8⁺ T cell immunity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.02.040

A preliminary evaluation of a recombinant circumsporozoite protein vaccine against Plasmodium falciparum malaria. RTS,S Malaria Vaccine Evaluation Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.02.040

Long-term protection against malaria after experimental sporozoite inoculation: an open-label follow-up study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.02.040

A clinical trial of prime-boost immunisation with the candidate malaria vaccines RTS,S/AS02A and MVA-CS.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.02.040

A consultation on the optimization of controlled human malaria infection by mosquito bite for evaluation of candidate malaria vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.02.040

Controlled human malaria infections by intradermal injection of cryopreserved Plasmodium falciparum sporozoites

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.02.040

Successful sporozoite challenge model in human volunteers with Plasmodium vivax strain derived from human donors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.02.040

Consistent safety and infectivity in sporozoite challenge model of Plasmodium vivax in malaria-naive human volunteers.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.02.040

Cloned cytotoxic T cells recognize an epitope in the circumsporozoite protein and protect against malaria

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.02.040

Priming with an adenovirus 35-circumsporozoite protein (CS) vaccine followed by RTS,S/AS01B boosting significantly improves immunogenicity to Plasmodium falciparum CS compared to that with either malaria vaccine alone

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.02.040

Recombinant viruses expressing a human malaria antigen can elicit potentially protective immune CD8+ responses in mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.02.040

Virosome-formulated Plasmodium falciparum AMA-1 & CSP derived peptides as malaria vaccine: randomized phase 1b trial in semi-immune adults & children

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.02.040

Genome sequence of the human malaria parasite Plasmodium falciparum

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.02.040

Comparative genomics of the neglected human malaria parasite Plasmodium vivax

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.02.040

Transgenic rodent Plasmodium berghei parasites as tools for assessment of functional immunogenicity and optimization of human malaria vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.02.040

Identification of Plasmodium falciparum antigens by antigenic analysis of genomic and proteomic data

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.02.040

MALVAC 2009: progress and challenges in development of whole organism malaria vaccines for endemic countries, 3-4 June 2009, Dakar, Senegal

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.02.040

Establishment of a human hepatocyte line that supports in vitro development of the exo-erythrocytic stages of the malaria parasites Plasmodium falciparum and P. vivax.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.02.040

Mechanisms underlying the monocyte-mediated antibody-dependent killing of Plasmodium falciparum asexual blood stages

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.02.040

Cutting edge: a new tool to evaluate human pre-erythrocytic malaria vaccines: rodent parasites bearing a hybrid Plasmodium falciparum circumsporozoite protein

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.02.040

What can transgenic parasites tell us about the development of Plasmodium-specific immune responses?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.02.040

A field trial to assess a blood-stage malaria vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.02.040

Pre-clinical assessment of novel multivalent MSP3 malaria vaccine constructs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.02.040

A recombinant blood-stage malaria vaccine reduces Plasmodium falciparum density and exerts selective pressure on parasite populations in a phase 1-2b trial in Papua New Guinea

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.02.040

Report of a consultation on the optimization of clinical challenge trials for evaluation of candidate blood stage malaria vaccines, 18-19 March 2009, Bethesda, MD, USA.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.02.040

Erythrocyte and reticulocyte binding-like proteins of Plasmodium falciparum

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.02.040

The blood-stage malaria antigen PfRH5 is susceptible to vaccine-inducible cross-strain neutralizing antibody

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.02.040

Can growth inhibition assays (GIA) predict blood-stage malaria vaccine efficacy?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.02.040

Evidence for the involvement of VAR2CSA in pregnancy-associated malaria

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.02.040

Global genetic diversity and evolution of var genes associated with placental and severe childhood malaria

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.02.040

Identification and characterization of B-cell epitopes in the DBL4ε domain of VAR2CSA

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.02.040

A long neglected world malaria map: Plasmodium vivax endemicity in 2010

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.02.040

A new world malaria map: Plasmodium falciparum endemicity in 2010

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.02.040

Changes in malaria indices between 1999 and 2007 in The Gambia: a retrospective analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.02.040

Effect of a fall in malaria transmission on morbidity and mortality in Kilifi, Kenya

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.02.040

Revisiting the basic reproductive number for malaria and its implications for malaria control

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.02.040

Phase 1 trial of malaria transmission blocking vaccine candidates Pfs25 and Pvs25 formulated with montanide ISA 51.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.02.040

Phase 1 vaccine trial of Pvs25H: a transmission blocking vaccine for Plasmodium vivax malaria

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.02.040

Phase I/IIa safety, immunogenicity, and efficacy trial of NYVAC-Pf7, a pox-vectored, multiantigen, multistage vaccine candidate for Plasmodium falciparum malaria.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.02.040

What should vaccine developers ask? Simulation of the effectiveness of malaria vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.02.040

10.1016/J.VACCINE.2013.02.040

7 January 2021

Identifiers

DOI

1 reference

1 August 2017

1 reference